- $3.27bn
- $2.44bn
- $218.71m
Ideaya Eye Cancer Drug Combo Meets Main Goal Of Mid: to-late-stage trial (updated)
Ideaya eye cancer drug meets main goal of mid-to-late-stage trial
Brief: Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman
U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
U.S. STOCKS ON THE MOVE-Marvell Technology, Tempus AI, Energy Vault
U.S. STOCKS ON THE MOVE-Tesla, CoreWeave, Kymera
IDEAYA rises after lung cancer drug combo testing deal with AstraZeneca
Brief: Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali
U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget
U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis
U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa
Brief: IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Ideaya Biosciences Rises As Early: stage cancer trial starts
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM
U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
Brief: Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma